Health
FDA Approves First Nonhormonal Hot Flash Pill
Health Points
- The FDA has approved Lynkuet (elinzanetant), a new nonhormonal prescription pill for moderate to severe hot flashes.
- Lynkuet targets brain receptors that control body temperature and reduced hot flashes by 55 percent in clinical studies.
- While side effects are usually mild, liver function testing is recommended before and during treatment.
A new nonhormonal pill, Lynkuet, will soon be available for people experiencing moderate to severe hot flashes, a common menopause symptom.
This innovative medication works by targeting specific brain receptors to help manage body temperature, offering an option for those who cannot or choose not to use hormone therapy.
“Having safe and effective nonhormonal options for treatment of bothersome hot flashes is tremendously important,” says JoAnn E. Manson, MD, MPH, DrPH, professor at Harvard Medical School.
Clinical studies showed Lynkuet reduced both the frequency and intensity of hot flashes and also improved quality of sleep for many participants.
Common side effects were headache and fatigue, but doctors recommend liver function tests before starting Lynkuet and again after three months.
Another nonhormonal option called Veozah is available, but it works differently and may not be suitable for all women due to potential drug interactions or liver risks.
Lynkuet is expected to cost about $650 a month without insurance but may be as low as $25 monthly with coverage.
If you’re experiencing menopause symptoms and considering your treatment choices, talk to your healthcare provider to see if a nonhormonal pill like Lynkuet may be right for you.